Small-molecule antivirals treatment for Covid-19: A systematic review and network meta-analysis

Supplemental Materials for "Small-molecule antivirals treatment for Covid-19: A systematic review and network meta-analysis".
Our study was registered on PROSPERO (CRD42023396617) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The protocol was also showed . The study characteristics about 92 RCTs and 68 retrospective studies were shown. We utilized the revised Cochrane Risk of Bias tool for RCTs and the Newcastle Ottawa Scale (NOS) for retrospective studies. A total of 92 RCTs were included, of which 42 RCTs were comprehensively evaluated as "High risk" due to allocation concealment and blinding, 15 RCTs were evaluated as "Unclear risk" due to blinding and other biases. A total of 67 retrospective studies were included, of which 34 were mainly downgraded for the typicality of the exposed study, comparability of studies on the basis of the design or analysis, and adequacy of follow up of cohorts.